Efficacy and Safety of Secukinumab in the Treatment of Generalized Pustular Psoriasis in Children: A Series of Three Clinical Cases
Current Pediatrics · 14.11.2026 · 25 (5) · 486-498
DOI: 10.15690/vsp.v25i5.3098 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Pediatrics, online erschienen am 14.11.2026. Verfasst von Nikolay N. Murashkin und 8 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Treating generalized pustular psoriasis (GPP) in children presents a complex clinical challenge due to the potentially high toxicity of conventional immunosuppressants and the lack of biologic agents specifically approved for this age group. In this context, it is highly relevant to gather data on the use of secukinumab—an interleukin (IL)-17A inhibitor—for GPP in an off-label capacity, particularly in patients who have experienced inadequate responses to, intolerance of, or have contraindications to standard therapies. Case reports. This report presents observations of three patients with GPP. Patient G., a 6-year-and-5-month-old boy, showed an inadequate response to acitretin and experienced delayed physical development. Patient M., a 2-year-old child, presented with GPP in combination with Wilson’s disease. Patient D., a 12-year-and-3-month-old girl, had a severe form of the disease, complicated by concomitant psoriatic arthritis and a thrombocytopathy. In all three cases, a medical board authorized the initiation of off-label treatment with secukinumab. The treatment resulted in the complete resolution of skin lesions; the first patient also showed a recovery in the rate of physical development. No adverse events were recorded during the course of secukinumab therapy.
Conclusion
This series of clinical cases demonstrates that secukinumab can achieve a significant clinical response in children with GPP, particularly when retinoids prove ineffective or when the use of methotrexate is contraindicated due to underlying comorbidities. The experience gained suggests that IL-17A inhibitors may be considered a potential therapeutic option for severe generalized pustular psoriasis (GPP) in children, particularly in cases where standard immunosuppressants are ineffective or contraindicated.
Zitieren
APA
Murashkin, N. N., Ufimceva, A. Y., Elakova, A. V., Bulokhova, E. S., Epishev, R. V., Opryatin, L. A., Ivanov, R. A., Leonova, M. A., & Ivanchikov, V. V. (2026). Efficacy and Safety of Secukinumab in the Treatment of Generalized Pustular Psoriasis in Children: A Series of Three Clinical Cases. Current Pediatrics, 25(5), 486-498. https://doi.org/10.15690/vsp.v25i5.3098
Vancouver
Murashkin NN, Ufimceva AY, Elakova AV, Bulokhova ES, Epishev RV, Opryatin LA, et al. Efficacy and Safety of Secukinumab in the Treatment of Generalized Pustular Psoriasis in Children: A Series of Three Clinical Cases. Current Pediatrics. 2026;25(5):486-498. doi:10.15690/vsp.v25i5.3098
BibTeX
@article{Murashkin2026,
author = {Murashkin, Nikolay N. and Ufimceva, Anastasia Yu. and Elakova, Anastasia V. and Bulokhova, Ekaterina S. and Epishev, Roman V. and Opryatin, Leonid A. and Ivanov, Roman A. and Leonova, Maria A. and Ivanchikov, Vladislav V.},
title = {Efficacy and Safety of Secukinumab in the Treatment of Generalized Pustular Psoriasis in Children: A Series of Three Clinical Cases},
journal = {Current Pediatrics},
year = {2026},
volume = {25},
number = {5},
pages = {486--498},
doi = {10.15690/vsp.v25i5.3098}
}
EUVIMED